Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPlastic/Reconstructive SurgeryAetna Cosmetic Surgery Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0031

    Cosmetic Surgery and Procedures

    Customize your policy alerts

    Sign up for Aetna Policy 0031 alerts

    Get alerted when Policy 0031 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for cosmetic surgery and procedures, specifying which procedures may be medically necessary and which are considered cosmetic or investigational; applies to Aetna plans and providers seeking coverage determinations.

    Policy Summary
    PayerAetna
    PolicyCosmetic Surgery and Procedures
    Policy CodePolicy 0031
    Change TypeNo material change
    Effective DateAug 3, 1995
    Last ReviewFeb 8, 2024
    Next Review DateJan 11, 2024
    Key ActionObtain and submit documentation (e.g., photos, letters, clinical records) and verify prior authorization when asserting medical necessity for procedures with cosmetic aspects.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30+procedures listed as cosmetic
    Manymedically necessary w/ CPBs
    CPT/HCPCScomprehensive code list
    24related CPBs referenced
    Qwo/DaxxifyFDA approvals cited

    Coverage Criteria

    Medically necessary procedures with CPB-based criteria

    Covered when ALL of the following are met

    General medical necessity: Procedure is needed to improve functioning of a body part or is medically necessary even if it also changes appearance; documentation (e.g., photographs, letters, chart records) may be required.

    Supported by policy introduction

    Procedure-specific CPB criteria: The following procedures are considered medically necessary when the specific criteria in the referenced CPBs are met: blepharoplasty (CPB 0084), breast reduction (CPB 0017 or CPB 0615), chemical peels/dermabrasion (CPB 0251), panniculectomy/abdominoplasty-related procedures (CPB 0211), rhinoplasty/septoplasty (CPB 0005), phalloplasty for gender-affirming surgery (CPB 0615), grafting of autologous fat for breast reconstruction (CPB 0185), and other procedures listed in the policy introduction when their individual CPB criteria are satisfied.

    See individual CPB references in document

    Cosmetic Exclusion (General)

    Not covered when cosmetic:

    Policy Summary
    PayerAetna
    PolicyCosmetic Surgery and Procedures
    Policy CodePolicy 0031
    Change TypeNo material change
    Effective DateAug 3, 1995
    Last ReviewFeb 8, 2024
    Next Review DateJan 11, 2024
    Key ActionObtain and submit documentation (e.g., photos, letters, clinical records) and verify prior authorization when asserting medical necessity for procedures with cosmetic aspects.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & AuthorizationBackgroundDefinitions
    Cosmetic exclusion: Surgical procedures directed at improving appearance are excluded from coverage; the underlying condition giving rise to the pre‑operative appearance is generally not a consideration. Only exceptions are prompt repair of accidental injury or improvement of a malformed body member that provides functional benefit.

    Policy background: cosmetic surgery exclusion

    Injectables and device-based treatments

    Covered when FDA-approved for specific indications and used for those indications:

    FDA-approved injectables/devices: Injectable or device-based products referenced in this policy are covered only when used for their FDA‑approved indications (e.g., Qwo [collagenase clostridium histolyticum‑aaes] for moderate‑to‑severe cellulite of the buttocks in adult women; Daxxify [daxibotulinumtoxinA‑lanm] for temporary improvement of moderate to severe glabellar lines in adults).meets FDA indication

    Coverage contingent on indication and any additional policy criteria or prior authorization requirements

    Liposuction for lipedema — indication criteria

    Surgical treatment (e.g., liposuction) for lipedema is considered when ALL of the following are met:

    Lipedema surgical indications: (1) A clinical diagnosis of lipedema established on the basis of medical history and characteristic clinical findings (symmetrical disproportionate increase of subcutaneous adipose tissue of the limbs, edema, easy bruising, tenderness); (2) Symptoms persist or there is progression despite thorough conservative therapy including complex physical therapy (manual lymphatic drainage, compression therapy, exercise, skin care); (3) Documented objective measurements and follow‑up plan (e.g., repeated waist and involved limb circumferences, BMI, assessment of function and psychosocial distress); (4) Patient has a suitable health profile for surgery (morbid obesity should be addressed prior to liposuction).

    Derived from guideline summaries and recommendations; tumescent liposuction is the surgical technique of choice when criteria met

    The policy enumerates a wide range of procedures that Aetna considers cosmetic and therefore excluded from coverage. Examples listed include: aesthetic alteration of the female genitalia (e.g., hymenoplasty, labiaplasty), aesthetic operations on the umbilicus, breast augmentation and mastopexy (breast lift), buttock lift/augmentation, cheek and chin implants, correction of diastasis recti, correction of inverted nipple, hair transplant for age-related thinning, testicular prostheses except when replacing congenitally absent or lost testes for medical reasons, ear/body piercing, electrolysis/laser hair removal (except as specified for gender dysphoria), thigh/arm/submental/other regional excisions (thighplasty, arm lift, etc.), eyebrow/eyelash tattooing, mesotherapy, neck tucks, tattoo removal, and treatment with small or large gel-particle hyaluronic acid fillers for cosmetic contouring. This list is illustrative of the many procedures in the policy characterized as cosmetic and subject to exclusion unless a narrow exception applies (for example, prompt repair after accidental injury or reconstruction of a malformed body member that provides functional benefit).

    Aetna’s policy states that procedures performed primarily to improve appearance are excluded as cosmetic; the underlying condition that produces the preoperative appearance is generally not a basis for coverage. The policy further identifies specific CPT/ICD-10 entries and diagnostic conditions that may be treated as exclusion triggers when used to justify cosmetic procedures, including diagnoses such as F45.22 (body dysmorphic disorder), F52.0–F52.9 / F64.0–F66 (sexual and gender identity disorders), and L68.0–L68.9 (hirsutism). Providers should note these codes when submitting claims and understand that claims driven by cosmetic indications may be denied unless they meet the narrow exceptions described in the policy.

    The document specifies that Qwo (collagenase clostridium histolyticum-aaes) must not be substituted for other injectable collagenase products. It also clarifies that Qwo is not indicated for the treatment of Peyronie’s disease or Dupuytren’s contracture; those conditions are addressed under separate CPBs referenced in the policy.

    Within the provided excerpts there are citations and case reports describing complications after eyebrow and eyelash tattooing (e.g., epithelioid granulomatous inflammation, peri-orbital pigmentation), but the policy text in these chunks does not state any explicit coverage exclusions or specific medical necessity criteria unique to eyebrow or eyelash tattooing. The document records reported adverse events and pathology findings without defining separate coverage rules for these procedures in the quoted sections.

    The policy explicitly lists numerous procedures as cosmetic and not medically necessary. Items called out include aesthetic genital procedures (labiaplasty, hymenoplasty, mons pexy), umbilical aesthetic operations, breast augmentation and mastopexy, buttock augmentation/lifts, facial implants (cheek, chin), mesotherapy, neck tucks, removal of frown lines/spider angioma, correction of moon face or tuberous breast deformity, tattoo removal, and tattooing/eyebrow or eyelash tattooing among others. Also noted are treatments with small and large gel-particle hyaluronic acid fillers for contouring and reducing depressions due to acne, injury, scars, or wrinkles when no functional impairment exists; these are considered cosmetic and not medically necessary.

    The policy describes that use of hyaluronic acid gel products (for example, Restylane, Perlane) to improve skin contour or reduce depressions from acne, injury, scars, or wrinkles is considered cosmetic because such contour irregularities are not deemed functional impairments. Systematic reviews cited in the policy document note evidence of safety and efficacy in certain facial areas, but the policy’s coverage determination treats these aesthetic indications as not medically necessary in the absence of functional deficit.

    The policy frames Qwo’s role narrowly: it recognizes Qwo as an FDA-approved collagenase formulation for cellulite but explicitly states that use of Qwo outside its approved cosmetic indication (for example, for Peyronie’s disease or Dupuytren’s contracture) is not appropriate. Thus, off-label uses are not supported by the language in these excerpts and Qwo should not be considered interchangeable with other collagenase products for non‑indicated conditions.

    The portions of the policy excerpt addressing eyebrow and eyelash tattooing summarize case reports of complications (granulomatous inflammation, peri-orbital pigmentation) and note that such procedures are commonly performed with a low reported complication rate. However, in these chunks the document does not set out specific not-medically-necessary (NMN) conditions or a separate NMN list tied specifically to tattooing or related cosmetic pigmenting procedures.

    Coding

    Coding
    Skin tag billing guidanceRemoval of skin tags: up to and including 15 lesions billed with 11200; additional lesions billed with +11201
    Coding
    Qwo dosing schedule0.84 mg per buttock administered as 12 subcutaneous injections per buttock; total 1.68 mg per treatment visit; 3 treatment visits at 21-day intervals
    Coding
    Daxxify dosing40 Units delivered in 5 intramuscular injections (8 Units each) to glabellar sites

    Provider Actions & Authorization

    Prior Authorization

    Prior Authorization for Selected CPTs and Injectables

    Prior authorization may be required for selected procedures and injectable/device administrations. Certain CPT and HCPCS codes listed in the policy (for example, injectable products and select procedural codes) are subject to prior review and require documentation that medical necessity criteria are met prior to payment.

    • Affected code sets include select CPT and HCPCS codes in the Applicable Codes sections (see policy code lists).
    • Prior authorization is routinely requested for injectable products such as daxibotulinumtoxinA (Daxxify), deoxycholic acid (J0591; Kybella), collagenase (J0775/Qwo), and other HCPCS Q-codes (e.g., Q2026, Q2028).
    Prior Authorization

    Prior Authorization for Deoxycholic Acid (Kybella) Off‑Label Uses

    Requests for off‑label use of deoxycholic acid (Kybella) for body areas other than persistent submental fat should include the FDA‑approved indication and supporting clinical evidence demonstrating medical necessity for the off‑label region. Coverage for off‑label DCA use is evaluated on a case‑by‑case basis and may require prior authorization.

    • Document FDA‑approved indication (persistent submental fat) when applicable.
    • For off‑label requests, provide literature, clinical rationale, and patient‑specific anatomic/clinical details to justify medical necessity.
    Prior Authorization

    Prior Authorization May Be Required for Specific Injectables/Devices

    Some injectables and device products are specifically listed as not covered for the indications shown; others may require prior authorization depending on the plan. Check the Applicable CPT/HCPCS lists and submit prior authorization when indicated.

    • HCPCS J0591 (deoxycholic acid) and J0775 (collagenase) appear in the HCPCS lists; plan coverage varies by indication and may require prior review.
    • Certain HCPCS codes are explicitly listed as not covered for the indications in this policy (see 'HCPCS codes not covered' list).
    Denial Risk

    Denial Risk for Cosmetic / Non‑Medically Necessary Procedures

    The policy reserves the right to deny coverage for procedures performed primarily for cosmetic purposes. Procedures intended to improve appearance without a documented medical necessity are excluded and may be denied.

    • Cosmetic exclusion applies to surgical/procedural interventions directed at improving appearance.
    • Exceptions exist when a procedure is medically necessary to improve function, treat disease, repair an injury, or correct a congenital defect — documentation must support the indication.
    Denial Risk

    Cosmetic Exclusion / Denial Risk

    Procedures directed at improving appearance are excluded as cosmetic unless criteria demonstrating medical necessity are met. Claims with cosmetic indications may be denied unless the request meets the stated medical‑necessity criteria and plan exceptions.

    • Surgeries to correct the result of injury, post‑mastectomy reconstruction, and specified congenital defect repairs may be covered — verify against plan language.
    • Providers should attach clinical records demonstrating functional impairment or disease‑directed need when submitting authorization requests.
    Billing Rule

    Specific ICD‑10 Denial Triggers

    Certain ICD‑10 diagnosis codes are identified as potential denial triggers when used for cosmetic indications. Use appropriate, disease‑specific ICD‑10 codes that substantiate medical necessity rather than cosmetic intent.

    • ICD‑10 codes listed as not covered for cosmetic indications include F45.22 (body dysmorphic disorder), F52.0–F52.9, F64.0–F66 (sexual and gender identity disorders), and L68.0–L68.9 (hirsutism).
    • Covered diagnosis examples (when criteria met) include B20, E88.1, L71.1, L91.0, and others listed in the Applicable Codes section.
    Denial Risk

    Qwo Substitution / Indication Risk

    Qwo (collagenase clostridum histolyticum‑aaes) must not be substituted for other collagenase products and is only indicated for cellulite in the buttocks; use for Peyronie’s disease or Dupuytren’s contracture is outside the indicated use and may lead to denial.

    • Do not substitute Qwo for other collagenase formulations.
    • Qwo is FDA‑approved for moderate to severe cellulite of the buttocks in adult women only; requests for other indications should cite appropriate coverage policies for those conditions.
    Note

    Prior Authorization Not Specified / Not Applicable Content

    Some items in the policy are informational only or have no specified prior authorization requirement in this section. When prior authorization is not specified, follow customary plan administrative rules and consult benefit documents.

    • Eyebrow and eyelash tattooing have no specified prior authorization requirements in this section but are generally considered cosmetic and may be denied when performed for appearance alone.
    • When the policy does not specify prior authorization, providers should verify benefit plan requirements and submit clinical documentation if coverage is sought.
    Documentation Required

    Documentation to Support Medical Necessity

    Providers must submit documentation to support medical necessity with authorization requests. This includes clinical notes, photographs, operative reports, letters describing functional impairment, conservative therapy attempts, and any relevant histopathologic or imaging findings.

    • Photographs, chart records, and letters documenting medical necessity may be required for many procedures (e.g., blepharoplasty, liposuction for lipedema).
    • For lipedema, include documentation of conservative therapy (manual lymphatic drainage, compression therapy, exercise, skin care) prior to surgical consideration.
    Billing Rule

    Coding Documentation

    Accurate coding and submission of applicable procedure and diagnosis codes is required. Some HCPCS codes are listed as covered only if selection criteria are met, while other HCPCS/CPT/ICD‑10 codes are explicitly not covered for certain indications.

    • Submit the appropriate CPT/HCPCS procedure codes and ICD‑10 diagnosis codes that reflect medical necessity rather than cosmetic intent.
    • Refer to the 'Applicable CPT / HCPCS / ICD‑10 Codes' lists in the policy for covered vs not‑covered codes and for codes that may trigger additional review.
    Documentation Required

    Lipedema Diagnostic and Documentation Expectations

    For lipedema, diagnosis should be established by history and clinical findings. Providers should document symptom progression, prior conservative treatments, and measurements (e.g., limb circumferences, BMI) when requesting coverage for liposuction or other surgical interventions.

    • Diagnosis based on localized, symmetrical increase in subcutaneous adipose tissue disproportionate to trunk, with edema, easy bruising, and tenderness.
    • Document trials of conservative therapy (manual lymphatic drainage, compression, exercise, skin care), objective measures (waist/limb circumferences, BMI), and impact on function prior to surgery.
    Step Therapy

    Step Therapy

    Step therapy requirements are not described for collagenase (Qwo) or other products in this section; when step therapy is relevant, it will be specified in the applicable coverage criteria or benefit documents.

    • No step therapy rules for Qwo are listed in this policy section.
    • Verify plan‑specific medical management rules (step therapy, quantity limits) during prior authorization.

    Background

    Background: Aetna excludes coverage for cosmetic surgery and procedures that are not medically necessary. Procedures that are needed to improve the functioning of a body part, to treat injury, disease, or congenital defects, or that meet specific CPB criteria (for example, reconstruction following mastectomy or surgery for gender dysphoria when criteria are met) may be covered even if they also alter appearance. The policy underscores that cosmetic procedures intended solely to improve appearance are excluded and may be denied.

    Definitions

    inv-41: Medically necessary — definition
    DefinitionA surgery or procedure needed to improve the functioning of a body part or otherwise medically necessary even if it also changes appearance
    Documentation noteDocumentation may be required to support the medical necessity claim
    Coverage implicationProcedures meeting this definition may be covered despite cosmetic aspects
    inv-42: Cosmetic surgery exclusion
    DefinitionExclusion precluding payment for surgical procedures directed at improving appearance (cosmetic)
    ExceptionsPrompt repair of accidental injury or improvement of a malformed body member that provides functional benefit are exceptions
    Policy effectClaims for procedures performed to improve appearance may be denied under this exclusion
    inv-43: Qwo
    Generic nameCollagenase clostridium histolyticum‑aaes
    Brand nameQwo (Endo Aesthetics LLC)
    FDA indicationFDA‑approved injectable for treatment of moderate‑to‑severe cellulite of the buttocks in adult women
    Dosing summary0.84 mg per buttock administered as 12 subcutaneous injections per buttock; 3 treatment visits at 21‑day intervals
    inv-44: Daxxify
    Generic nameDaxibotulinumtoxinA‑lanm injection
    Brand nameDaxxify (Revance Therapeutics, Inc.)
    FDA indicationFDA‑approved for temporary improvement of moderate to severe glabellar (frown) lines in adults
    Dosing summary40 Units delivered as 5 intramuscular injections of 8 Units each to specific glabellar sites
    inv-45: Lipedema
    Core featuresChronic disorder in women with abnormal adipose deposition in the lower extremities leading to bilateral enlargement from hips to ankles
    SymptomsPain, bruising, edema; may progress to secondary lymphedema and fibrosis in later stages
    Management contextConservative therapy (manual lymphatic drainage, compression garments) is standard; liposuction is a surgical option in selected cases
    inv-46: Daxxify (duplicate product definition entry)
    Product identificationDaxibotulinumtoxinA‑lanm injection (daxibotulinumtoxinA‑lanm)
    BrandDaxxify (Revance Therapeutics, Inc.)
    Regulatory statusFDA‑approved for temporary improvement of moderate to severe glabellar lines in adults
    inv-47: Granulomatous hypersensitivity / foreign body epithelioid granuloma
    Histopathologic featuresOrganized epithelioid cell granulomas with occasional Langhans‑type giant cells and often minimal pigment
    Etiology linkAssociated with cosmetic eyebrow tattooing and metal elements (e.g., copper, iron, cobalt, chromium) in inks
    Clinical relevanceReported as a complication of eyebrow tattooing in case reports and series
    inv-48: Dermal fibrosis (post-tattooing)
    DefinitionHistopathologic finding of increased dermal fibrous tissue (dermal fibrosis) observed after eyebrow tattooing
    Imaging correlateAssociated with thicker peri‑ocular soft tissues on ultrasonography compared to non‑tattooed controls
    Surgical implicationHigher rates of dermal fibrosis and occasional wound complications observed in subjects with prior eyebrow tattooing